Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance

Cancer Medicine

Volumn 1, Issue 3, 2012, Pages 328-337

  Gohno, Tatsuyuki ^a   Seino, Yuko ^a,b   Hanamura, Toru ^a   Niwa, Toshifumi ^a   Matsumoto, Mitsuyo ^a   Yaegashi, Nobuo ^a   Oba, Hanako ^b   Kurosumi, Masafumi ^b   Takei, Hiroyuki ^b   Yamaguchi, Yuri ^b   Hayashi, Shin ichi ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

Author keywords

Breast cancer; ERE transcriptional activity; Estrogen receptor ; Ki67; Luminal A

Indexed keywords

ADENOVIRUS VECTOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GREEN FLUORESCENT PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CORRELATION ANALYSIS; DRUG SENSITIVITY; ER GENE; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PGR GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

EID: 84885402246     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.41     Document Type: Article

References (29)

1. Hammond, M. E., D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty, S. Badve, et al. 2010. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28:2784-2795.
2. Burstein, H. J., A. A. Prestrud, J. Seidenfeld, H. Anderson, T. A. Buchholz, N. E. Davidson, et al. 2010. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28:3784-3796.
3. Dowsett, M., C. Allred, J. Knox, E. Quinn, J. Salter, C. Wale, et al. 2008. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol. 26:1059-1065.
4. Yerushalmi, R., R. Woods, P. M. Ravdin, M. M. Hayes, and K. A. Gelmon 2010. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174-183.
5. Badve, S., D. Turbin, M. A. Thorat, A. Morimiya, T. O. Nielsen, C. M. Perou, et al. 2007. FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clin. Cancer Res. 13:4415-4421.
6. Kouros-Mehr, H., E. M. Slorach, M. D. Sternlicht, and Z. Werb 2006. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127:1041-1055.
7. Albergaria, A., J. Paredes, B. Sousa, F. Milanezi, V. Carneiro, J. Bastos, et al. 2009. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 11:R40.
8. Pujol, P., J. P. Daures, S. Thezenas, F. Guilleux, P. Rouanet, and J. Grenier 1998. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 83:698-705.
9. Rutanen, E. M., F. Pekonen, T. Nyman, and T. Wahlström 1993. Insulin-like growth factors and their binding proteins in benign and malignant uterine diseases. Growth Regul. 3:74-77.
10. O'Toole, S. A., E. Dunn, B. L. Sheppard, O. Sheils, J. J. O'Leary, W. Wuttke, et al. 2005. Oestrogen regulated gene expression in normal and malignant endometrial tissue. Maturitas 51:187-198.
11. Hayashi, S. I., H. Eguchi, K. Tanimoto, T. Yoshida, Y. Omoto, A. Inoue, et al. 2003. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr. Relat. Cancer 10:193-202.
12. Hayashi, S., T. Niwa, and Y. Yamaguchi 2009. Estrogen signaling pathway and its imaging in human breast cancer. Cancer Sci. 100:1773-1778.
13. Campbell, R. A., P. Bhat-Nakshatri, N. M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri 2001. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276:9817-9824.
14. Stoica, G. E., T. F. Franke, M. Moroni, S. Mueller, E. Morgan, M. C. Iann, et al. 2003. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22:7998-8011.
15. Inoue, A., N. Yoshida, Y. Omoto, S. Oguchi, T. Yamori, R. Kiyama, et al. 2002. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J. Mol. Endocrinol. 29:175-192.
16. Inoue, A., Y. Omoto, Y. Yamaguchi, R. Kiyama, and S. I. Hayashi 2004. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J. Mol. Endocrinol. 32:649-661.
17. Yoshida, N., Y. Omoto, A. Inoue, H. Eguchi, Y. Kobayashi, M. Kurosumi, et al. 2004. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci. 95:496-502.
18. Matsumoto, M., H. Sakamoto, Y. Yamaguchi, Y. Seino, H. Takei, M. Kurosumi, et al. 2009. 3-Dimensional microarray analysis of estrogen signal-related genes in breast cancer tissues. Anticancer Res. 29:3971-3975.
19. Omoto, Y., Y. Kobayashi, K. Nishida, E. Tsuchiya, H. Eguchi, K. Nakagawa, et al. 2001. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem. Biophys. Res. Commun. 285:340-347.
20. Matsumoto, M., Y. Yamaguchi, Y. Seino, A. Hatakeyama, H. Takei, H. Niikura, et al. 2008. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr. Relat. Cancer 15:451-463.
21. Kurosumi, M. 2003. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients. Breast Cancer 10:97-104.
22. Allred, D. C., J. M. Harvey, M. Berardo, and G. M. Clark 1998. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11:155-168.
23. Elston, C. W., and I. O. Ellis 1991. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410.
24. Ackerman, G. E., M. E. Smith, C. R. Mendelson, P. C. MacDonald, and E. R. Simpson 1981. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J. Clin. Endocrinol. Metab. 53:412-417.
25. Tokuda, E., Y. Seino, A. Arakawa, M. Saito, F. Kasumi, S. I. Hayashi, et al. 2012. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. Treat. 133:427-436.
26. Yamaguchi, Y., H. Takei, K. Suemasu, Y. Kobayashi, M. Kurosumi, N. Harada, et al. 2005. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res. 65:4653-4662.
27. Gauduchon, J., F. Gouilleux, S. Maillard, V. Marsaud, J. M. Renoir, and B. Sola 2005. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin. Cancer Res. 11:2345-2354.
28. Safe, S., and K. Kim 2004. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog. Nucleic Acid Res. Mol. Biol. 77:1-36.
29. Hewitt, S. C., and K. S. Korach 2002. Estrogen receptors: structure, mechanisms and function. Rev. Endocr. Metab. Disord. 3:193-200.